Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334539 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
A Phase 2 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT03334539: Completed Phase 2 study, sponsored by HanAll BioPharma Co..
NCT03334539 is a Phase 2 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03334539, a Phase 2 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Primary Outcome
It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.
Interventions
- BIOLOGICAL HL036 ophthalmic solution
- OTHER Placebo vehicle solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-11-05 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 2 |
What the finished NCT03334539 record still lists
NCT03334539 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which HL036 ophthalmic solution is the first listed.
NCT03334539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03334539 about?
NCT03334539 is a clinical study titled "A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes". The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT03334539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-11-05. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT03334539?
The interventions under investigation include: HL036 ophthalmic solution (BIOLOGICAL), Placebo vehicle solution (OTHER).
Who is sponsoring clinical trial NCT03334539?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03334539's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI